Close Menu

NEW YORK — Swiss diagnostics firm Quotient on Monday reported a nearly 9 percent year-over-year increase in fiscal first quarter revenues driven by its Alba reagent business.

For the three-month period ended June 30, Quotient's revenues climbed to $8.9 million, generated almost entirely from Alba sales, from $8.2 million the year before. Sales of the company's COVID-19 antibody test, which runs on its MosaiQ platform for blood grouping and transfusion-transmitted infection screening, were $111,000 in the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.